- Home
- HRMY vs EVCM Comparison
HRMY vs EVCM Comparison
Compare HRMY & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | EVCM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.2B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HRMY | EVCM |
|---|---|---|
| Price | $28.44 | $11.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 7 |
| Target Price | ★ $46.70 | $10.67 |
| AVG Volume (30 Days) | ★ 586.8K | 143.2K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 145.45 |
| EPS | ★ 2.71 | 0.10 |
| Revenue | ★ $868,453,000.00 | $588,907,000.00 |
| Revenue This Year | $19.75 | $7.39 |
| Revenue Next Year | $12.88 | $5.84 |
| P/E Ratio | ★ $10.19 | $114.00 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $7.66 |
| 52 Week High | $40.87 | $14.41 |
Technical Indicators
Market Signals| Indicator | HRMY | EVCM |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 51.94 |
| Support Level | $27.66 | $10.78 |
| Resistance Level | $28.99 | $12.01 |
| Average True Range (ATR) | 0.78 | 0.64 |
| MACD | 0.32 | 0.05 |
| Stochastic Oscillator | 78.96 | 68.99 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. The Company served more than 745,000 customers across three core verticals: EverPro for Home Services; EverHealth for Health Services; and EverWell for Wellness Services. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty.